GVK Biosciences announces multi-year drug discovery collaboration with the Moulder Center for Drug Discovery Research, Temple University
GVK Biosciences announced today that it has entered into a drug discovery alliance with the Moulder Center for Drug Discovery Research at Temple University. As part of the multi-year integrated drug discovery collaboration, GVK BIO will be responsible for the target validation, lead identification and lead optimization of small molecules in selected therapeutic areas, including cardiovascular, metabolic, and central nervous system disorders.
The Moulder Center is a unique, fully integrated state-of-the-art drug discovery center that is used for both internal research within Temple University and for external collaborations with pharmaceutical and biotech companies and other universities. As part of the collaboration, GVK BIO will apply their integrated drug discovery expertise and technologies to identify interesting small molecules against selected targets. GVK Biosciences will be responsible for reagent generation, assay development and establishing the screening cascade leading to lead identification and optimization. Moulder Center and GVK BIO will be jointly responsible for designing the molecules for this program. The molecules will be optimized and progressed through lead optimization to a pre-clinical candidate.
“Utilizing GVK BIO’s discovery chemistry and biology capabilities, we look forward to working with the Moulder Center for Drug Discovery Research. Dr. Magid Abou-Gharbia, is a world renowned researcher with more than 26 years of research experience and we are pleased to be working with him. This collaboration with Temple University is among several academic collaborations GVK BIO has with leading research institutions. ” said Manni Kantipudi, Chief Executive Officer, GVK Biosciences.
“This business model reflects the increasing trend of collaborations between academic centers of excellence and pharmaceutical companies to discover new drugs.” said Dr. Magid Abou-Gharbia, Director of the Moulder Center for Drug Discovery Research and Associate Dean for Research in Temple’s School of Pharmacy “We are delighted to be working with GVK BIO’s experienced research and discovery team to further leverage both teams’ talents to identify innovative drug candidates”.
A number of medicines for which authorisation in the European Union (EU) was primarily based on clinical studies conducted at GVK Biosciences in Hyderabad, India should be suspended, says the European Medicines Agency (EMA). The recommendation is based on findings from an inspection that ra ... more
GVK Biosciences (GVK BIO) announced that it was awarded the Frost & Sullivan 2011 Best Practices Award for Growth Leadership in the Contract Research Services Market.
The Frost & Sullivan Award for Growth Leadership is presented to the company that has demonstrated excellence in capturing a ... more
GVK Biosciences Private Limited (GVK BIO) announced that it received full accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC) International for its animal facilities.
The accreditation demonstrates GVK BIO’s commitment to high standard ... more
GVK Biosciences, Asia’s leading Contract Research Organization, delivers integrated research services to big Pharma and Biotech companies globally. GVK BIO accelerates the Drug Discovery and Development process of its customers through science and innovation. GVK BIO has a diverse customer ... more
In a major collaborative effort, researchers at the Lewis Katz School of Medicine at Temple University and the University of Nebraska Medical Center (UNMC) have for the first time eliminated replication-competent HIV-1 DNA - the virus responsible for AIDS - from the genomes of living animal ... more
Mitochondria are the energy-generating batteries of cells, but they also perform other critical functions, including protecting cells against calcium overload, a significant cause of cell death in certain cardiovascular and neurodegenerative diseases. Underlying this safety mechanism is a p ... more
Cancer cells with mutations in BRCA1 or BRCA2 genes, which serve a vital role in preserving the integrity of the genetic code, are key targets for cancer therapeutics. Yet, few agents can selectively eliminate cells deficient in BRCA, and none can do so without the risk of inducing drug res ... more